Want to see SRPT full AI Analyst Report?
Revenue by Segment
Splits revenue across business lines and markets — for example commercial product sales, collaboration or licensing income, and geographic regions — to reveal where growth is coming from and how diversified the business is. Helps investors see whether Sarepta depends mainly on commercial sales from a small set of drugs, benefits from partner deals or milestone payments, and how exposure to different markets or revenue types affects risk and upside.Products revenue showed a big build into 2024 and then trended down into early‑2026, reflecting uneven Alevitus commercialization and timing-driven one‑time therapy dynamics; Collaboration & Other is extremely lumpy and Q1‑2026 contains a large non‑cash Roche item that materially inflates headline revenue. Management’s reiterated guidance and strong gross margins support financial stability, but underlying product momentum is gradual and dependent on demand recovery and small safety cohorts—so focus on product revenue trajectory and upcoming clinical/regulatory readouts, not the headline collaboration spikes.
Date | Products | Collaboration and Other |
|---|---|---|
Jun 30, 2026 | $328.69M | $72.56M |
Mar 31, 2026 | $330.51M | $400.29M |
Dec 31, 2025 | $369.61M | $73.33M |
Sep 30, 2025 | $370.04M | $29.31M |
Jun 30, 2025 | $513.12M | $97.97M |
Mar 31, 2025 | $611.52M | $133.33M |
Dec 31, 2024 | $638.16M | $20.25M |
Sep 30, 2024 | $429.77M | $37.40M |
Jun 30, 2024 | $360.55M | $2.38M |
Mar 31, 2024 | $359.48M | $53.98M |